U.S. Policy Missteps Could Send Biotech Overseas, Biogen Idec CEO Warns
This article was originally published in PharmAsia News
Executive Summary
U.S. policy decisions over the next 12 to 24 months could strengthen the nation's biotechnology industry or send it and the capital market on which it depends to places like China, India and Singapore that are "poised to take over what we've started," Biogen Idec CEO James Mullen said Nov. 2
You may also be interested in...
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required.)